These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25822571)

  • 21. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
    León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
    APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotype-specific anti-Dengue virus NS1 mouse antibodies cross-react with prM and are potentially involved in virus production.
    Masrinoul P; Omokoko MD; Pambudi S; Ikuta K; Kurosu T
    Viral Immunol; 2013 Aug; 26(4):250-8. PubMed ID: 23941673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.
    da Silva Voorham JM; Rodenhuis-Zybert IA; Ayala Nuñez NV; Colpitts TM; van der Ende-Metselaar H; Fikrig E; Diamond MS; Wilschut J; Smit JM
    PLoS One; 2012; 7(3):e29957. PubMed ID: 22431958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of a virus-specific continuous B-cell epitope on the PrM/M protein of Japanese Encephalitis Virus: potential application in the detection of antibodies to distinguish Japanese Encephalitis Virus infection from West Nile Virus and Dengue Virus infections.
    Hua RH; Chen NS; Qin CF; Deng YQ; Ge JY; Wang XJ; Qiao ZJ; Chen WY; Wen ZY; Liu WX; Hu S; Bu ZG
    Virol J; 2010 Sep; 7():249. PubMed ID: 20858291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.
    Chan AH; Tan HC; Chow AY; Lim AP; Lok SM; Moreland NJ; Vasudevan SG; MacAry PA; Ooi EE; Hanson BJ
    PLoS One; 2012; 7(4):e33451. PubMed ID: 22509258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
    Fink AL; Williams KL; Harris E; Alvine TD; Henderson T; Schiltz J; Nilles ML; Bradley DS
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
    Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
    Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of B cell epitopes of dengue virus 2 NS3 protein by monoclonal antibody.
    Tian Y; Chen W; Yang Y; Xu X; Zhang J; Wang J; Xiao L; Chen Z
    Appl Microbiol Biotechnol; 2013 Feb; 97(4):1553-60. PubMed ID: 23081772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative contribution of dengue prM- and E-specific polyclonal antibodies to neutralization and enhancement.
    Rodpothong P; Boonarkart Ch; Ruangrung K; Onsirisakul N; Kanistanon D; Auewarakul P
    Acta Virol; 2016; 60(3):249-59. PubMed ID: 27640435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.
    Frei JC; Kielian M; Lai JR
    Virology; 2015 Nov; 485():371-82. PubMed ID: 26339794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
    Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
    Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation and analysis of dengue virus enhancing and neutralizing activities using simple high-throughput assays.
    Li XQ; Chen J; Huang YF; Ding XX; Liu LD; Qiu LW; Pan YX; Deng YQ; Hu DM; Di B; Qin CF; Che XY
    Appl Microbiol Biotechnol; 2013 Jul; 97(14):6503-11. PubMed ID: 23760532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional properties of DENV EDIII‑reactive antibodies in human DENV‑1‑infected sera and rabbit antiserum to EDIII.
    Chen J; Wen K; Li XQ; Yi HS; Ding XX; Huang YF; Pan YX; Hu DM; Di B; Che XY; Fu N
    Mol Med Rep; 2016 Aug; 14(2):1799-808. PubMed ID: 27357403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.